Form 4: Adaptive Biotechnologies Executive Sells Shares to Cover Tax Obligations After RSU Vesting

Susan Bobulsky, Chief Commercial Officer, MRD at Adaptive Biotechnologies, sold shares to cover tax obligations related to the vesting of Restricted Stock Units (RSUs) and acquired stock options.

Summary

• Susan Bobulsky, Chief Commercial Officer, MRD at Adaptive Biotechnologies, reported changes in beneficial ownership.
• On March 4, 2024, Bobulsky acquired 132,979 shares of common stock at $0 and was granted options to purchase 199,549 shares at an exercise price of $3.99, exercisable starting March 4, 2025.
• On March 5, 2024, she sold 6,016 shares at $3.43 and 6,975 shares at $3.44 to cover tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Bobulsky directly owns 248,290 shares of common stock and options to purchase 199,549 shares.
• The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions related to equity compensation. While the sale of shares is a reduction in holdings, it is primarily for tax purposes and doesn't necessarily indicate a negative outlook. The acquisition of stock options is a positive sign.

Positives

• The acquisition of 132,979 shares at $0 indicates an increase in holdings.
• The grant of options to purchase 199,549 shares suggests a potential for future gains if the stock price increases above the exercise price of $3.99.

Negatives

• The sale of 12,991 shares was required to cover tax obligations, reducing the overall shareholding.

Risks

• The value of the stock options is dependent on the future performance of Adaptive Biotechnologies' stock.
• The 'sell to cover' transaction to meet tax obligations can limit the executive's ability to benefit fully from stock appreciation.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the stock options suggests a long-term incentive for the executive.

Management Comments

• The sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The 'sell to cover' mechanism is a common practice to manage tax obligations related to equity compensation.

Comparison to Industry Standards

• The 'sell to cover' practice is widely used across the biotechnology industry among companies like Illumina, Inc. and Genentech to manage tax obligations related to equity compensation.
• Option grants with vesting schedules are standard practice to align executive compensation with long-term company performance, similar to compensation structures at companies like Amgen and Gilead Sciences.

Stakeholder Impact

• The sale of shares could have a minor, temporary impact on the stock price.
• The equity compensation structure aims to align management's interests with those of shareholders.

Key Dates